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Abstract
We aimed to validate the prognostic association of p16 expression in ovarian high-grade serous carcinomas
(HGSC) and to explore it in other ovarian carcinoma histotypes. p16 protein expression was assessed by clinical-
grade immunohistochemistry in 6525 ovarian carcinomas including 4334 HGSC using tissue microarrays from
24 studies participating in the Ovarian Tumor Tissue Analysis consortium. p16 expression patterns were inter-
preted as abnormal (either overexpression referred to as block expression or absence) or normal (heterogeneous).
CDKN2A (which encodes p16) mRNA expression was also analyzed in a subset (n = 2280) mostly representing
HGSC (n = 2010). Association of p16 expression with overall survival (OS) was determined within histotypes as
was CDKN2A expression for HGSC only. p16 block expression was most frequent in HGSC (56%) but neither pro-
tein nor mRNA expression was associated with OS. However, relative to heterogeneous expression, block expres-
sion was associated with shorter OS in endometriosis-associated carcinomas, clear cell [hazard ratio (HR): 2.02,
95% conﬁdence (CI) 1.47–2.77, p < 0.001] and endometrioid (HR: 1.88, 95% CI 1.30–2.75, p = 0.004), while
absence was associated with shorter OS in low-grade serous carcinomas (HR: 2.95, 95% CI 1.61–5.38,
p = 0.001). Absence was most frequent in mucinous carcinoma (50%), and was not associated with OS in this
histotype. The prognostic value of p16 expression is histotype-speciﬁc and pattern dependent. We provide deﬁn-
itive evidence against an association of p16 expression with survival in ovarian HGSC as previously suggested.
Block expression of p16 in clear cell and endometrioid carcinoma should be further validated as a prognostic
marker, and absence in low-grade serous carcinoma justiﬁes CDK4 inhibition.
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Introduction
CDKN2A (cyclin-dependent kinase inhibitor 2A) is
located on chromosome 9p21.3 and encodes two pro-
teins, p16 and p14ARF, that have different reading
frames [1]. p14ARF inhibits p53 function and p16
inhibits the CDK4/6 complex acting as a negative cell
cycle regulator suppressing the transition from the
Gap1 to DNA synthesis (G1/S) phase and arresting the
cell cycle in the G1 phase [2]. Normal cells express
variable amounts of p16 protein that can be detected by
immunohistochemistry (IHC) in both nuclear and cyto-
plasmic localizations (heterogeneous p16 expression
pattern) [3]. There are two abnormal p16 expression
patterns: absent and overexpressed, the latter also
referred to as block expression as recommended by the
Lower Anogenital Squamous Terminology Standardi-
zation Project for HPV-Associated Lesions (LAST)
[4]. In keeping with its role as a tumor suppressor,
absence of p16 expression can occur due to various
mechanisms including homozygous deletion, loss of
function mutations, promoter hypermethylation and
translational suppression [5]. In ovarian carcinoma,
homozygous deletion of CDKN2A has been detected in
only 3% of high-grade serous carcinomas (HGSC) [6],
15% of low-grade serous carcinomas (LGSC) [7], and
in 30% of mucinous carcinomas (MC) [8]. In contrast,
p16 block expression results from a variety of alter-
ations in G1/S cell cycle transition as a compensatory
effort to inhibit G1/S transition. p16 block expression
is classically observed in human papillomavirus
(HPV)-associated uterine cervical neoplasms, in which
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viral proteins (E7) inactivate pRB and promote G1/S
transition [9,10]. IHC overexpression of p16 is rou-
tinely used in clinical diagnostics for identiﬁcation of
HPV-related neoplasms. Ovarian carcinomas are not
associated with HPV infections, but alterations promot-
ing G1/S transition are common, e.g. RB1, CCNE1,
CCND1, or MYC [6].
Ovarian carcinoma is a biologically heterogeneous
disease [11] composed of ﬁve main histotypes: HGSC,
LGSC, clear cell carcinoma (CCC), endometrioid carci-
noma (EC), and MC, which should be studied sepa-
rately [12]. Older studies combining all histotypes
showed that either overexpression or complete absence
of p16 were associated with unfavorable outcomes
[13–15]. Recently, histotype-speciﬁc studies also
reported that normal heterogeneous p16 expression was
signiﬁcantly associated with longer progression-free
and overall survival (OS) in two series of 334 and
115 women with HGSC [16,17]. Therefore, we hypoth-
esized that heterogeneous p16 expression reﬂecting the
normal G1/S transition status is associated with a favor-
able outcome in HGSC compared to absent or block
expression reﬂecting abnormalities of the G1/S cell
cycle checkpoint complex. The purpose of this study
was to validate whether abnormal p16 expression is
associated with an unfavorable OS in HGSC, and to
explore prognostic associations in other histotypes
using tissue microarrays (TMAs) from the Ovarian
Tumor Tissue Analysis (OTTA) consortium [18,19].
Methods
Immunohistochemistry
The study investigators obtained tissue from 7492
patients with a diagnosis of primary ovarian, fallopian
tube, or peritoneal carcinoma from 24 study sites
(Supporting Information, Table S1). Most of these
patients also participated in previous OTTA studies
[18–20], and all studies received ethics board approval
for tumor proﬁling. TMAs were constructed contain-
ing 1–6 cores of 0.6–1.0 mm in diameter from
formalin-ﬁxed parafﬁn embedded tissue representing
tumor from each patient. p16 IHC was performed cen-
trally at two institutions: Genetic Pathology Evaluation
Centre, University of British Columbia, and Calgary
Laboratory Services, University of Calgary, Canada.
TMAs were stained in ﬁve batches with three different
protocols (Table S2) using the same antibody (clone
E6H4, CINtec, mtm laboratories). Three staining pat-
terns were recorded: absent, heterogeneous and block
(Figure S1). Block expression was distinguished from
heterogeneous staining by using the recommendation
for p16 interpretation from LAST [4]; that is, block
expression is characterized by diffuse staining of
tumor cells in nuclear and/or cytoplasmic compartment
with at least moderate intensity with virtually no nega-
tive tumor cell clusters. Interobserver reproducibility
between two observers (PR and MK) was assessed for
a subset of 120 cases. Seventeen studies were scored
by PR and the remainder by MK. Cases represented
by more than one core and discordant cores were con-
solidated as heterogeneous if any of a given case score
was heterogeneous.
CDKN2A mRNA analysis
A subset of 2280 cases had CDKN2A mRNA expression
data from NanoString n-counter analysis. RNA was
extracted from 10 μm sections from formalin ﬁxed paraf-
ﬁn embedded (FFPE) tissue blocks, which were macro-
dissected to avoid adjacent benign tissue but included
tumor stroma using the Qiagen miRNeasy (Qiagen Inc.
Toronto, Ontario, Canada) FFPE protocol and quanti-
tated on a Nanodrop spectrophotometer (Thermo-Fisher
Scientiﬁc, Waltham, MA, USA). After mixing 500 ng of
total RNA per sample with a custom codeset
(NanoString Technologies Inc, Seattle, WA, USA) and
hybridization buffer (NanoString), hybridization was per-
formed using a Tetrad 2 thermal cycler (Bio Rad Labora-
tories Inc, Hercules, CA, USA) for 16 or 20 h and then
analyzed on a nCounter Digital Analyzer (NanoString).
Data was normalized to housekeeping genes (RPL19,
ACTB, PGK1, SDHA, and POLR1B) and pre-processed
to a reference of 3 pooled ovarian cancer specimens as
described previously [21]. We interrogated the cBiopor-
tal for associations of CDKN2A alterations with OS in
HGSC from TCGA [22,23].
Statistical tests
Morphology-based histotype was derived from pathol-
ogy reports with or without review of reports or slides
(Table S1). Because some HGSC were mistakenly
classiﬁed as other histotypes in the past, we used the
highly speciﬁc WT1(+)/p53(mutant) IHC combination
to reclassify those to HGSC [24]. We excluded
409 cases owing to diagnosis other than the ﬁve major
histotypes, 393 cases being uninterpretable, 31 cases
with a combination of absence and block staining, and
134 cases with missing clinical follow-up data. The
ﬁnal sample size was 6525 (Table 1). The median time
from diagnosis to enrollment was 0 days (interquartile
range 0–182 days). Patients (n = 331) with missing
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data for either age or time from diagnosis to enrolment
were not part of the multivariate survival analysis.
Associations of p16 IHC expression and CDKN2A
mRNA expression with demographic and clinical vari-
ables were examined using the chi-square test and
Kruskal–Wallis test, as appropriate. We examined
interobserver heterogeneity of p16 interpretation using
Kappa coefﬁcients. For individuals with multiple
tumor cores, we examined intratumoral heterogeneity
of p16 expression using percent discordance. We
assessed correlations between (the ordinally scaled)
p16 staining values and CDKN2A mRNA expression
using Pearson correlation coefﬁcients.
The primary end point for survival analysis was death
from any cause. We chose right censoring of follow-up
at 12 years post-diagnosis to mitigate against deaths from
noncancer-related causes. Kaplan–Meier survival curves
and corresponding log-rank tests were generated to visu-
ally assess associations of p16 expression with survival.
Cox proportional hazards regression was used for multi-
variable assessment of hazard ratios (HRs). Models were
adjusted for the following confounding factors: study
site, age (continuous), FIGO stage (categorized into I/II,
III/IV, and missing variable), and residual disease (cate-
gorized as absent, i.e. no residual disease, present, and
missing). We used left truncation to account for the
enrollment of prevalent cases in some studies. We tested
whether histotype modiﬁed the association between p16
IHC expression and OS by ﬁtting and testing corre-
sponding interaction terms. We assessed the functional
form of the association between CDKN2A mRNA
expression levels and OS in HGSC using penalized B-
splines [25], adjusting for the same potential
confounding variables as described above. All statistical
tests were two-sided, and analyses were carried out using
RStudio (Boston, MA, USA) or JMP 13.0.0 (SAS, Cary,
NC, USA). This study adhered to the REMARK cri-
teria [26].
Results
p16 protein and CDKN2A mRNA expression across
histological types
Table 1 shows the characteristics of the study sample.
The histotype distribution is similar to population-based
cohorts except for a slightly higher frequency of MC
[27]. Inter-observer agreement for interpretation of p16
IHC was excellent (Cohen’s kappa of 0.92). Of the 6525
women, 4046 (62.0%) had more than one interpretable
tissue core and, of those, 12.9% had a discordant inter-
pretation between cores. This moderate degree of intratu-
moral heterogeneity was not statistically different
between histotypes (p = 0.11), ranging from 7.4% for
LGSC to 16.3% for CCCs. As expected, the distribution
of p16 expression categories was signiﬁcantly different
across histotypes (Table 2, p < 0.0001) [28].
A subset of 2280 cases (2010 HGSC, 22 LGSC,
139 EC, 82 CCC, and 27 MC) had corresponding
CDKN2A mRNA expression data. CDKN2A mRNA
expression was signiﬁcantly higher in HGSC [normal-
ized mean −2.98 (95% CI -3.06 to −2.90)] compared
to LGSC [normalized mean −4.90 (95% CI −5.39 to
−3.19)], EC [normalized mean −4.82 (95% CI −5.31
to −4.33)], CCC [normalized mean −4.16 (95% CI
Table 1. Clinical characteristics
High-grade
serous carcinoma
Low-grade
serous carcinoma
Clear cell
carcinoma
Endometrioid
carcinoma
Mucinous
carcinoma
Number of cases, n (%) 4334 (66.4) 205 (3.1) 717 (11.0) 882 (13.5) 387 (5.9)
Age at diagnosis, years, mean  SD 59.7  10.7 53.8  12.7 56.0  11.4 54.8  12.0 54.5  14.8
Stage, n (%)
I/II 822 (19.5) 62 (32.3) 550 (78.2) 703 (83.5) 283 (81.9)
III/IV 3402 (80.5) 130 (67.7) 154 (21.8) 139 (16.5) 67 (19.1)
Unknown 110 13 13 40 37
Macroscopic residual disease, n (%)
Absent 1028 (43.7) 64 (49.6) 349 (81.0) 393 (88.3) 163 (77.2)
Present 1323 (54.3) 65 (50.4) 82 (19.0) 52 (11.7) 51 (23.8)
Unknown 1983 76 286 437 173
Outcome
Five year survival, %  SE1 40.7  0.8 61.9 3.7 63.4  1.9 81.0  1.5 65.3  2.7
Total months followed for censored patients, months, mean  SD1 87  41 80  43 104  39 101  39 97  41
p16 expression, n (%)
Heterogeneous 1627 (37.5) 167 (81.5) 471 (65.7) 676 (76.7) 171 (44.2)
Absent 267 (6.2) 25 (12.2) 146 (20.4) 127 (14.4) 194 (50.1)
Block 2440 (56.3) 13 (6.3) 100 (13.9) 79 (8.9) 22 (5.7)
1Follow-up is right-censored at 12 years post-diagnosis.
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−4.51 to −3.81)] and MC [normalized mean −4.50
(95% CI −5.07 to −3.93), for all p < 0.0001]. We con-
ﬁrmed the bimodal distribution of CDKN2A mRNA
expression in HGSC as previously observed in the
TCGA data set [22,23] (Figure S2). CDKN2A mRNA
expression correlated with p16 IHC scores (r = 0.69)
overall, and for the speciﬁc histotypes (r = 0.69 for
HGSC, 0.57 for LGSC, 0.62 for CCC, 0.80 for EC
and 0.69 for MC, Figure 1A).
Association of p16 protein and CDKN2A mRNA
expression and OS in HGSC and LGSC
For HGSC patients, the Kaplan–Meier survival curve
showed no difference in OS for the three p16 immuno-
histochemical expression patterns (Figure 1B,
p = 0.32), which was supported by HRs near 1.0 after
controlling for the study, age, time to enrollment, stage
and residual disease (Table 2).
For mRNA expression in HGSC, we used several
different groupings (median split, tertiles) as well as
different cut-offs for dichotomization (mean = −3.03,
visual inspection to separate bimodal peaks = −3.7)
but there was no association of CDKN2A mRNA
levels with OS. Alternatively, we examined the func-
tional form of the association between CDKN2A
expression and OS in HGSC using penalized B splines
[25]. Analyses revealed relatively ﬂat HRs across the
entire spectrum of mRNA values with a 95% conﬁ-
dence band that always included an HR of 1.0
(Figure S3). By interrogating 489 HGSC from TCGA
via the cBioPortal [22,23], 92 (19%) showed downre-
gulation of CDKN2A, which was also not associated
with survival (p = 0.27).
In contrast, for patients with LGSC, the 5-year sur-
vival rate was signiﬁcantly lower in tumors with
absent p16 expression (Figure 1C, 43.4%, SE 10.7%)
and in tumors with block p16 expression (42.2%, SE
14.7%) compared to heterogeneous expression
(70.1%, SE 3.8%, p = 0.0005). This was also signiﬁ-
cant in multivariate analysis for the absence of p16
(Table 2). The limited number of CDKN2A mRNA
expression values for non-HGSC precluded us from
examining associations within those histotypes.
No association of p16 protein expression and
OS in MC
Figure 1D shows no differences in 5-year survival for
MC with heterogeneous (63.7%, SE 3.8%), absent
(73.3%, SE 3.2%) or block expression (72.2%, SE
9.7%, p = 0.12). There was no signiﬁcant association
in multivariate analysis (Table 2).
Association of p16 protein expression and OS in
endometriosis related ovarian carcinomas
For CCC, 5-year survival was more than 20% lower
for women with tumor block expression of p16
(45.2%, SE 5.0%) compared to heterogeneous staining
(67.0%, SE 2.2%, p < 0.0001, Figure 1E). Similarly,
for EC, 5-year survival was more than 20% lower for
women with tumor block expression of p16 (63.0%,
SE 5.8%) compared to heterogeneous staining (85.0%,
SE 1.4%, p < 0.0001, Figure 1F) or absent staining
(85.2%, SE 3.3). In multivariate analysis, there was a
signiﬁcantly increased risk of death for patients with
CCC or EC block staining, with HRs of 2.02 (95% CI:
1.47–2.77) and 1.88 (95% CI: 1.30–2.75), respectively
(Table 2).
Pooled association of p16 protein expression and
OS, and tests of effect modiﬁcation by histotype
In analyses that combined all ﬁve major histological
subtypes, women whose tumors exhibited with block
expression had poorer OS (HR 1.13, 95% CI 1.06–1.22)
than those with absent or heterogeneous expression
(Figure S4). The associations between p16 expression
and survival were strikingly different across histotypes
(Cox regression test for interaction p = 1.4 × 10−8).
Association of p16 protein expression with
clinicopathological parameters within histotypes
In EC, a greater proportion of cases with p16 block
expression were diagnosed at stage III/IV (33.8%
compared to 14.5% for heterogeneous staining,
Table 2. Association of p16 expression and OS by histotype
Histotype Expression N HR (95% CI) P value
High-grade serous Heterogeneous 1550 ref 0.68
Absent 244 1.06 (0.90–1.25)
Block 2292 1.03 (0.95–1.11)
Low-grade serous Heterogeneous 166 ref 0.001
Absent 25 2.95 (1.61–5.38)
Block 13 1.54 (0.72–3.29)
Clear cell Heterogeneous 463 ref <0.001
Absent 138 0.67 (0.47–0.96)
Block 92 2.02 (1.47–2.77)
Endometrioid Heterogeneous 650 ref 0.004
Absent 117 0.98 (0.66–1.45)
Block 73 1.88 (1.30–2.75)
Mucinous Heterogeneous 163 ref 0.80
Absent 187 1.05 (0.72–1.55)
Block 21 1.28 (0.61–2.64)
Adjusted for study, age, time interval, stage and residual tumor; ref, reference.
Smaller sample size is due to availability of age and time interval information.
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p < 0.0001) and grade 3 (45.7% compared to 16.0%
for heterogeneous staining, p < 0.0001, Table S3).
CCC cases with p16 block expression were more
likely to have residual disease at initial surgery (34.6%
compared to 17.1% for heterogeneous staining,
p = 0.0067). In LGSC, p16 expression was not
associated with age, stage or presence of residual
tumor. Associations for HGSC and MC are shown in
Table S3. Notably, there was no association for p16
expression status with BRCA1 or BRCA2 mutation sta-
tus for the subset of HGSCs with available mutation
data (n = 1370, p = 0.43).
Figure 1. Associations of p16 protein expression with CDKN2A mRNA expression and survival by histotype. (A) Comparison of CDKN2A
mRNA values (y-axis) with p16 scoring categories (x-axis), by the ﬁve major histotypes. a = p16 absence, h = p16 heterogeneous,
b = p16 block score, respectively. Kaplan–Meier OS curves of p16 expression within (B) high-grade serous, (C) low-grade serous,
(D) mucinous, (E) clear cell and (F) endometrioid carcinoma.
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Discussion
Our investigation showed that associations of p16
staining pattern with OS differ across ovarian carci-
noma histotypes. Block p16 expression was signiﬁ-
cantly associated with shorter survival for
endometriosis-related ovarian carcinomas. In contrast,
absence of p16 expression predicted shorter survival in
LGSC while no survival associations are observed for
MC and HGSC.
In contrast to previous studies [16,17], we provide
strong evidence against a clinically or biologically rel-
evant survival association of p16 expression in HGSC.
Our large sample size greatly reduces the potential of
this lack of association being a false negative ﬁnding.
Using our observed sample size and a two-sided test
of hypothesis with Type I error rate of 0.05, we would
have 80% power to detect a HR as low as 1.21 com-
paring absence and 1.10 comparing block to heteroge-
neous expression, respectively. This null conclusion is
supported by a lack of association between OS and
CDKN2A mRNA expression data, which correlated
positively with p16 IHC-based protein expression. In
keeping with the recommendations from the Institute
of Medicine for validation of biomarker studies [29],
we used the same antibody and the same scoring sys-
tem as previous studies. We found excellent interob-
server reproducibility regarding the IHC interpretation
and similar frequencies of the three staining patterns in
HGSC compared to previous studies; and it is, there-
fore, unlikely that technical or interpretational differ-
ences can explain differences in our results from those
published previously. We think that the large sample
size used in the current study compared to prior stud-
ies of HGSC avoided a false positive ﬁnding [16,17].
Since p16 block staining is a surrogate for various reti-
noblastoma pathway alterations, we speculate that dif-
ferent underlying alteration might explain the lack of
outcome associations for p16. For example, prognosti-
cally opposing underlying alterations (e.g. favorable
pRB loss versus unfavorable CCNE1 ampliﬁcations),
which result in the same p16 block staining, may neu-
tralize each other [30,31].
Exploring other histotypes, we demonstrate for the
ﬁrst time that block p16 expression is signiﬁcantly
associated with OS in both endometriosis-associated
histotypes: EC and CCC. Overall, those histotype-
speciﬁc differences would not have been revealed in a
combined histotype analysis and corroborate that bio-
marker analyses should be done stratiﬁed by histotype
[12]. Yet the subsets of p16 block expression that were
signiﬁcantly associated with unfavorable prognosis
were small: 9 and 14% of EC and CCC, respectively.
EC is usually associated with a favorable outcome and
some patients do not require chemotherapy or could
be considered for hormonal therapy if hormone recep-
tors (ER, PGR) are expressed [18,32]. However, estro-
gen receptor positive Luminal B breast cancers with
loss of pRB function and high p16 expression are
unresponsive to hormonal therapy [33]. Our data sug-
gest that further study of p16 as part of a biomarker
panel that identiﬁes EC with unfavorable prognosis
would help triage patients to earlier aggressive therapy
in the low stage setting, which may not be amenable
to hormonal therapy.
We observed a similar negative association between
block p16 expression and OS for CCC. Women
diagnosed with CCC have a relatively unfavorable
prognosis, in part because these tumors are
chemotherapy-resistant and alternative therapeutic
options are sparse [34]. Among those, radiation has
been suggested for CCC [35] and perhaps p16 expres-
sion can be assessed for prediction of response to
radiation as suggested from other cancer sites [3,36].
The survival associations speciﬁcally observed for
p16 block staining in the two endometrioisis-
associated histotypes somewhat serves as a cross-vali-
dation. Yet it does not preclude differences in the
underlying mechanisms, e.g. CCNE1 copy number
gain and overexpression have been reported for CCC
but not EC [37]. As a limitation, we observed a mod-
erate degree of intratumoral heterogeneity, which was
highest in CCC, using TMAs in size akin to pretreat-
ment omental core biopsies. However, CCCs are usu-
ally treated by upfront surgery and the p16
assessment on a full histological section should miti-
gate against intratumoral heterogeneity.
We also observed a signiﬁcant association with OS
in patients with LGSC. In contrast to the block stain-
ing in endometriosis-associated carcinomas, complete
absence was associated with unfavorable outcome in
LGSC in keeping with the tumor suppressor function.
Although investigating the underlying mechanism of
absence of p16 expression is beyond the scope of the
current study, the 12% of LGSC showing complete
absence of p16 by IHC is strikingly similar to the 15%
frequency of the homozygous deletion of the CDKN2A
locus reported by Hunter et al [7]. We have previously
shown that progesterone receptor (PGR) expression is
a favorable prognostic factor in LGSC [18]. Perhaps
PGR and p16 status could help to stratify LGSC
regarding prognosis [38]. Another consideration is the
possible predictive utility of absent p16 expression for
CDK4 inhibitors as suggested in clinical trials for
breast and other cancers [39]. Konecny et al demon-
strated that low p16 expression in pRB-proﬁcient
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tumors was correlated with in vitro response to CDK4
inhibitors [40]. Since other treatment options are lim-
ited for LGSC, this may represent an interesting option
for recurrent LGSC, a disease often affecting younger
women. There was a non-signiﬁcant trend for the few
LGSC with p16 block expression to have an unfavor-
able outcome but CKD4 inhibitors will be ineffective
in tumors with p16 block expression because p16
block expression already indicates futile intrinsic
CDK4 inhibition.
There was no signiﬁcant prognostic association of
p16 expression within MCs despite their having the
highest frequency of complete absence (50%) across
histotypes. This frequency is slightly higher than the
39% (n = 12/31) frequency of the combined corre-
sponding molecular alterations (homozygous CDKN2A
deletion or loss of functional mutations) reported by
Ryland et al [8]. Absence of p16 expression was most
frequently observed in low stage MC and we speculate
that a portion of those may be from low transcriptional
activity.
A strength of this study is the large sample size
providing excellent power to examine differences in
protein expression patterns for the most common his-
totype (HGSC) as well as reasonable power to dis-
cern differences within EC and CCC. The lower
sample sizes for MC and LGSC reduced our ability
to detect differences. We used a diagnostic bio-
marker panel of WT1/p53 to limit the number of
misclassiﬁed HGSC into other histotype categories.
Within the OTTA consortium, we had the opportu-
nity to analyze protein and mRNA data. Survival
analyses were adjusted for confounding factors such
as age, stage and residual disease. As a limitation,
some of the study sites did not collect detailed treat-
ment data; as such adjustment for treatment was not
feasible. However, cases were collected throughout
an era of relatively homogeneous standard adjuvant
therapy consisting of platinum-taxane chemotherapy
before the introduction of neoadjuvant chemotherapy
or PARP inhibitors.
This large-scale collaborative study did not validate
p16 expression as a prognostic marker in HGSC. The
frequent block expression as a surrogate for abnormal
retinoblastoma pathway activation warrants further
study of individual pathway members. The intriguing
prognostic associations in endometriosis-associated EC
and CCC make p16 a promising prognostic biomarker
that requires further independent validation. The
absence of p16 in a subset of LGSC calls for indepen-
dent validation as a prognostic marker as well as
investigation as a predictive marker for CDK4
inhibitors.
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line) and block staining (right-most line)
Figure S4. Kaplan–Meier overall survival curves of p16 expression in pooled analysis combining all histotypes
Table S1. Participating studies
Table S2. Immunohistochemical staining protocols
Table S3. Association of p16 expression with clinicopathological parameters
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